RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

Inclusion Criteria * Women aged at least 18 years; * Patients must be able to provide informed consent and sign the informed consent form to participate in the RDA study before any study procedures starts; * Newly diagnosed clinical stage I, II or III breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal; * Tumour size at least 1 cm in one dimension by clinical or radiographic exam (WHO criteria); * Must have histological confirmation of invasive breast cancer of any subtype or grade; * Patient is scheduled for neoadjuvant chemotherapy +/- antibodies and +/- other drugs according to Standard of Care; * Patient willing to have 2 research core needle biopsies (for RDA) taken at 2 collection timepoints during neoadjuvant chemotherapy treatment. Exclusion Criteria * Patient who has had prior local (i.e. surgery or radiotherapy) or systemic (i.e. endocrine or cytotoxic) therapy for the current breast cancer; * Participation in another interventional clinical trial with concurrent treatment with experimental drugs to treat the current breast cancer during the period of neoadjuvant therapy (from diagnosis until surgery); * Stage IV breast cancer; * Bilateral or multicentric breast tumour; * Prior malignant disease except curatively treated in-situ maligancies; * Concurrent pregnancy; * Breast feeding woman; * Concurrent medical, psychiatric or addictive disorders that may limit the ability to give informed consent or complete the trial; * Reasons indicating risk of poor compliance with study procedures; * Patient not able to consent;